US4031203A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hepatitis A antigen
Assignee: Merck and Co Inc
•
Filing: 1976-06-07
•
Granted: 1977-06-21
•
Expires: 1996-06-07
Abstract
Abstract Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
Inventors
- 👤 Philip J. Provost
- 👤 Oswald L. Ittensohn
- 👤 Maurice R. Hilleman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 22:55
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5768; C; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/32011; C12N2770/32411; C12N2770/32434; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
104 words
A method for obtaining hepatitis A antigen in an amount effective to complex hepatitis A antibody comprising inoculating a non-human primate with hepatitis A virus, subsequently removing the liver at a time when the serum glutamic oxaloacetic transaminase enzyme and the serum isocitric dehydrogenase enzyme levels are elevated, perfusing the liver with physiological saline, comminuting the liver and adding saline to obtain a suspension containing from about 5% to about 25% by weight of liver, clarifying the suspension, treating the suspension with CsCl gradient and selecting material having a buoyant density of from about 1.32 g/cm 3 to about 1.36 g/cm 3 of CsCl.
Claim 2
Independent Claim
104 words
A method for obtaining hepatitis A antigen in an amount effective to complex hepatitis A antibody comprising inoculating a non-human primate with hepatitis A virus, subsequently removing the liver at a time when the serum glutamic oxaloacetic transaminase enzyme and the serum isocitric dehydrogenase enzyme levels are elevated, perfusing the liver with physiological saline, comminuting the liver and adding saline to obtain a suspension containing from about 5% to about 25% by weight of liver, clarifying the suspension, treating the suspension with CsCl gradient and selecting material having a buoyant density of from about 1.32 g/cm 3 to about 1.36 g/cm 3 of CsCl.
Claim 3
Dependent Claim
13 words
A method according to claim 1 wherein the non-human primate is a marmoset.
Claim 4
Dependent Claim
12 words
A method according to claim 2 wherein the marmoset is S. mystax.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-20 | 1980-12-20 | 1981-06-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-20 | 1984-12-20 | 1985-06-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-20 | 1988-12-20 | 1989-06-21 | $7700.00 | Window Closed / Lapsed |